Baidu
map

精神心理科

订阅

MedSci主页 / 所有栏目 / 精神心理科

INGREZZA治疗迟发性运动障碍的长期有效性

2019-10-03 Allan MedSci原创

INGREZZA迟发性运动障碍RE-KINECT试验
关注

Neurocrine生物科技公司近日宣布，每日一次的INGREZZA能够改善迟发性运动障碍（TD）患者的长期症状。

Neurocrine生物科技公司近日宣布，每日一次的INGREZZA能够改善迟发性运动障碍（TD）患者的长期症状。这项临床研究（RE-KINECT试验）是临床医生在TD患者中进行的最大规模研究。这些数据将在2019年10月3日至6日在圣地亚哥举行的2019年年度心理大会上发表。

迟发性运动障碍(Tardive dyskinesia, TD)是长期使用多巴胺受体阻滞剂后迟发发作的一种多动性运动障碍，这些阻滞剂主要是抗精神病药物以及止吐药甲氧氯普胺。TD的临床表现多种多样，包括舞蹈病、手足徐动症、肌张力障碍、静坐不能、刻板行为，罕见情况下还包括震颤。术语“迟发性”将这些运动障碍与急性运动障碍、帕金森综合征以及静坐不能相鉴别，后三者在使用抗精神病药后很快出现。


原始出处：

http://www.firstwordpharma.com/node/1670894#axzz611EW3gzs

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2034419, encodeId=ceb12034419cd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Mar 17 09:06:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933979, encodeId=eccc19339e9b5, content=<a href='/topic/show?id=5f6598551d' target=_blank style='color:#2F92EE;'>#INGREZZA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9855, encryptionId=5f6598551d, topicName=INGREZZA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Mon Jan 06 14:06:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368800, encodeId=e0c51368800d0, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Oct 05 00:06:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506891, encodeId=14bb15068914d, content=<a href='/topic/show?id=f9699460126' target=_blank style='color:#2F92EE;'>#迟发性运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94601, encryptionId=f9699460126, topicName=迟发性运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a73d9842028, createdName=xlxchina, createdTime=Sat Oct 05 00:06:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373480, encodeId=7e0d3e34804b, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Thu Oct 03 10:32:13 CST 2019, time=2019-10-03, status=1, ipAttribution=)]
    2020-03-17 经常头晕

    #迟发性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2034419, encodeId=ceb12034419cd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Mar 17 09:06:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933979, encodeId=eccc19339e9b5, content=<a href='/topic/show?id=5f6598551d' target=_blank style='color:#2F92EE;'>#INGREZZA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9855, encryptionId=5f6598551d, topicName=INGREZZA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Mon Jan 06 14:06:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368800, encodeId=e0c51368800d0, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Oct 05 00:06:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506891, encodeId=14bb15068914d, content=<a href='/topic/show?id=f9699460126' target=_blank style='color:#2F92EE;'>#迟发性运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94601, encryptionId=f9699460126, topicName=迟发性运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a73d9842028, createdName=xlxchina, createdTime=Sat Oct 05 00:06:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373480, encodeId=7e0d3e34804b, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Thu Oct 03 10:32:13 CST 2019, time=2019-10-03, status=1, ipAttribution=)]
    2020-01-06 canlab

    #INGREZZA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2034419, encodeId=ceb12034419cd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Mar 17 09:06:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933979, encodeId=eccc19339e9b5, content=<a href='/topic/show?id=5f6598551d' target=_blank style='color:#2F92EE;'>#INGREZZA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9855, encryptionId=5f6598551d, topicName=INGREZZA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Mon Jan 06 14:06:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368800, encodeId=e0c51368800d0, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Oct 05 00:06:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506891, encodeId=14bb15068914d, content=<a href='/topic/show?id=f9699460126' target=_blank style='color:#2F92EE;'>#迟发性运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94601, encryptionId=f9699460126, topicName=迟发性运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a73d9842028, createdName=xlxchina, createdTime=Sat Oct 05 00:06:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373480, encodeId=7e0d3e34804b, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Thu Oct 03 10:32:13 CST 2019, time=2019-10-03, status=1, ipAttribution=)]
    2019-10-05 FukaiBao

    #运动障碍#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2034419, encodeId=ceb12034419cd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Mar 17 09:06:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933979, encodeId=eccc19339e9b5, content=<a href='/topic/show?id=5f6598551d' target=_blank style='color:#2F92EE;'>#INGREZZA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9855, encryptionId=5f6598551d, topicName=INGREZZA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Mon Jan 06 14:06:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368800, encodeId=e0c51368800d0, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Oct 05 00:06:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506891, encodeId=14bb15068914d, content=<a href='/topic/show?id=f9699460126' target=_blank style='color:#2F92EE;'>#迟发性运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94601, encryptionId=f9699460126, topicName=迟发性运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a73d9842028, createdName=xlxchina, createdTime=Sat Oct 05 00:06:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373480, encodeId=7e0d3e34804b, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Thu Oct 03 10:32:13 CST 2019, time=2019-10-03, status=1, ipAttribution=)]
    2019-10-05 xlxchina

    #迟发性运动障碍#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2034419, encodeId=ceb12034419cd, content=<a href='/topic/show?id=45eb94588cd' target=_blank style='color:#2F92EE;'>#迟发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94588, encryptionId=45eb94588cd, topicName=迟发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Tue Mar 17 09:06:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933979, encodeId=eccc19339e9b5, content=<a href='/topic/show?id=5f6598551d' target=_blank style='color:#2F92EE;'>#INGREZZA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9855, encryptionId=5f6598551d, topicName=INGREZZA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Mon Jan 06 14:06:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368800, encodeId=e0c51368800d0, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Oct 05 00:06:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506891, encodeId=14bb15068914d, content=<a href='/topic/show?id=f9699460126' target=_blank style='color:#2F92EE;'>#迟发性运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94601, encryptionId=f9699460126, topicName=迟发性运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a73d9842028, createdName=xlxchina, createdTime=Sat Oct 05 00:06:00 CST 2019, time=2019-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373480, encodeId=7e0d3e34804b, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Thu Oct 03 10:32:13 CST 2019, time=2019-10-03, status=1, ipAttribution=)]
    2019-10-03 一天没事干

    很好的学习机会

    0

相关资讯

2019年帕金森病及相关疾病世界大会（IAPRD）：INGREZZA和Opicapone的全新数据

Neurocrine生物医学近日宣布，它将在IAPRD上展示其两项运动障碍实验的数据，以验证INGREZZA（缬氨苄嗪，美国FDA批准用于治疗迟发性运动障碍的首款药物）和opicapone（帕金森病研究性辅助治疗药物）的有效性和安全性。

Baidu
map
Baidu
map
Baidu
map